secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001125345-24-000151
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics TAMARACK Phase 2 data: 6-month rPFS 69-70%, ORR up to 40.6%, but 8 treatment-related deaths
--------------------------------------------------------------------------------

- 6-month radiographic PFS rate 69% (2.0 mg/kg) and 70% (2.7 mg/kg); median rPFS ~8.5 and 7.5 months (immature).
- Confirmed ORR 20.0% (2.0 mg/kg) and 40.6% (2.7 mg/kg) among RECIST-evaluable patients.
- Median 6 doses received (range 1-12); 25.6% (2.0 mg/kg) and 18.6% (2.7 mg/kg) remained on drug at data cutoff.
- Grade ≥3 TEAEs: 65.6% (2.0 mg/kg) and 62.8% (2.7 mg/kg); discontinuation rates 25.6% and 38.4%.
- 8 fatal treatment-related AEs (5 in 2.0 mg/kg, 3 in 2.7 mg/kg) including pneumonitis and cardiac events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000151/0001125345-24-000151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000151/mgnx-20240916.htm
  HTML page:      https://secwatch.observer/filing/0001125345-24-000151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer